Christopher Colameco
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Chronic Lymphocytic Leukemia Research, Cancer Genomics and Diagnostics, Cancer-related Molecular Pathways
Most-Cited Works
- → CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment(2014)343 cited
- → Self-renewal of CD133hi cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer(2016)174 cited
- → Early treatment-related neutropenia predicts response to palbociclib(2020)38 cited
- → Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer(2017)27 cited
- → Erratum to: Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer(2017)20 cited
- → A phase I trial of palbociclib and paclitaxel in metastatic breast cancer.(2014)17 cited
- → Abstract P6-13-08: Palbociclib and paclitaxel on an alternating schedule for advanced breast cancer: Results of a phase Ib trial(2016)5 cited
- → Abstract P4-13-04: Upregulation of cell cycle pathway genes without loss of RB1 contributes to acquired resistance to single-agent treatment with palbociclib in breast cancer(2016)4 cited
- → Characteristics of high risk breast cancer patients with mutations identified by multiplex panel testing.(2015)2 cited
- → Abstract P6-07-05: Mutational spectrum and tumor response in metastatic breast cancer(2016)1 cited